Schuchman, Matthew
Brady, Tammy M.
Glenn, Dorey A.
Tuttle, Katherine R.
Cara-Fuentes, Gabriel
Levy, Rebecca V.
Gonzalez-Vicente, Agustin
Alakwaa, Fadhl M.
Srivastava, Tarak
Sethna, Christine B.
Funding for this research was provided by:
NIDDK (U54DK083912)
Article History
Received: 26 September 2023
Accepted: 1 February 2024
First Online: 21 March 2024
Declarations
:
: A.G-V has no conflict of interest to report. C.Sethna was on an advisory board for Travere Therapeutics. K.R. Tuttle reports support from Eli Lilly; personal fees and other support from Boehringer Ingelheim; personal fees and other support from AstraZeneca; grants, personal fees and other support from Bayer AG; grants, personal fees and other support from Novo Nordisk; grants and other support from Goldfinch Bio; other support from Gilead; and grants from Travere outside the submitted work.
: The NEPTUNE study was approved by the Institutional Review Board (IRB) at each of the 29 participating sites. The NEPTUNE study protocol was reviewed and approved by University of Michigan Medical School (IRBMED), Approval Number HUM00158219.
: All procedures were approved by the University of Michigan Institutional Review Board.
: Written informed consent and/or assent was obtained from each participant and/or caregiver before joining the study.